Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Posted: May 15, 2022 at 2:13 am

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

Originally posted here:
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Related Posts